Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00507247 · ClinicalTrials.gov registry record · Phase 2

Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus

A Phase 2 study of Staphylococcus Aureus, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
11
Enrollment target
1
Study location

NCT00507247: Completed Phase 2 study of Staphylococcus Aureus, sponsored by M.D. Anderson Cancer Center.

NCT00507247 is a Phase 2 study of Staphylococcus Aureus that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants, below the 3,903-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00507247, a Phase 2 study of Staphylococcus Aureus, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

Primary Objective: Evaluate the efficacy and safety of daptomycin given for treatment of catheter-related bloodstream infections due to S. aureus bacteria with or without exchange of the central venous catheter (CVC) over guide wire in comparison with a historical control group of catheter-related S. aureus bacteremia treated with standard therapy (Vancomycin) or other active agents against staph aureus (such as beta-lactam antibiotics).

Primary Outcome

Clinical response of Daptomycin administered for treatment of catheter-related bloodstream infections due to Staphylococcus Aureus bacteria, evaluated within 7 weeks of initiating Daptomycin therapy.

Conditions Studied

Interventions

  • DRUG Daptomycin

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2006-05
Est. Completion 2012-09
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00507247 record still lists

NCT00507247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 3,903-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Staphylococcus Aureus appearing as the primary indexed condition, and to 1 intervention - of which Daptomycin is the first listed.

NCT00507247 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00507247 about?

NCT00507247 is a clinical study titled "Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus". Primary Objective: Evaluate the efficacy and safety of daptomycin given for treatment of catheter-related bloodstream infections due to S. aureus bacteria with or without exchange of the central venous catheter (CVC) over guide wire in comparison with a historical control group of catheter-related ...

What is the current status of trial NCT00507247?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2006-05. Estimated completion is 2012-09.

What conditions does trial NCT00507247 study?

This clinical trial studies the following conditions: Staphylococcus Aureus.

What interventions are being tested in trial NCT00507247?

The interventions under investigation include: Daptomycin (DRUG).

Who is sponsoring clinical trial NCT00507247?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00507247 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Staphylococcus Aureus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00507247's enrollment target sits among peer trials

11 9th of 8 the lowest of 8 other Staphylococcus Aureus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Staphylococcus Aureus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00507247, the US trial registry maintained by the National Library of Medicine. NCT00507247 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.